

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 September 14; 23(34): 6197-6370



**EDITORIAL**

- 6197** Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy

*Papamichael K, Cheifetz AS*

**MINIREVIEWS**

- 6201** Evidences supporting the vascular etiology of post-double balloon enteroscopy pancreatitis: Study in porcine model

*Latorre R, López-Albors O, Soria F, Morcillo E, Esteban P, Pérez-Cuadrado-Robles E, Pérez-Cuadrado-Martínez E*

**ORIGINAL ARTICLE****Basic Study**

- 6212** Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer

*Olsen RS, Nijm J, Andersson RE, Dimberg J, Wågsäter D*

- 6220** Moxibustion eases chronic inflammatory visceral pain through regulating MEK, ERK and CREB in rats

*Li ZY, Huang Y, Yang YT, Zhang D, Zhao Y, Hong J, Liu J, Wu LJ, Zhang CH, Wu HG, Zhang J, Ma XP*

- 6231** Changes of Ghrelin/GOAT axis and mTOR pathway in the hypothalamus after sleeve gastrectomy in obese type-2 diabetes rats

*Wang Q, Tang W, Rao WS, Song X, Shan CX, Zhang W*

- 6242** Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells

*Lu CJ, He YF, Yuan WZ, Xiang LJ, Zhang J, Liang YR, Duan J, He YH, Li MY*

- 6252** Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation

*Wei ZQ, Zhang YH, Ke CZ, Chen HX, Ren P, He YL, Hu P, Ma DQ, Luo J, Meng ZJ*

**Retrospective Cohort Study**

- 6261** Systemic immune-inflammation index for predicting prognosis of colorectal cancer

*Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR*

**Retrospective Study**

- 6273** Predictive factors for the failure of endoscopic stent-in-stent self-expandable metallic stent placement to treat malignant hilar biliary obstruction

*Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Watanabe K, Nakamura J, Kikuchi H, Waragai Y, Takasumi M, Sato Y, Hikichi T, Ohira H*

- 6281 Assessment of colon polyp morphology: Is education effective?

*Kim JH, Nam KS, Kwon HJ, Choi YJ, Jung K, Kim SE, Moon W, Park MI, Park SJ*

- 6287 Body mass index does not affect the survival of pancreatic cancer patients

*Jiang QL, Wang CF, Tian YT, Huang H, Zhang SS, Zhao DB, Ma J, Yuan W, Sun YM, Che X, Zhang JW, Chu YM, Zhang YW, Chen YT*

### Observational Study

- 6294 Access to biologicals in Crohn's disease in ten European countries

*Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodsky V, Baji P; Crohn's Disease Research Group*

- 6306 Temporal trends in the misdiagnosis rates between Crohn's disease and intestinal tuberculosis

*Seo H, Lee S, So H, Kim D, Kim SO, Soh JS, Bae JH, Lee SH, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD*

- 6315 Detection of metastatic cancer cells in mesentery of colorectal cancer patients

*Luo XL, Xie DX, Wu JX, Wu AD, Ge ZQ, Li HJ, Hu JB, Cao ZX, Gong JP*

- 6321 Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients

*Wang AJ, Peng AP, Li BM, Gan N, Pei L, Zheng XL, Hong JB, Xiao HY, Zhong JW, Zhu X*

### Randomized Controlled Trial

- 6330 Circular RNA hsa\_circ\_0000745 may serve as a diagnostic marker for gastric cancer

*Huang M, He Yr, Liang LC, Huang Q, Zhu ZQ*

- 6339 P2Y1R is involved in visceral hypersensitivity in rats with experimental irritable bowel syndrome

*Wu J, Cheng Y, Zhang R, Liu D, Luo YM, Chen KL, Ren S, Zhang J*

- 6350 Randomized controlled trial of uncut Roux-en-Y vs Billroth II reconstruction after distal gastrectomy for gastric cancer: Which technique is better for avoiding biliary reflux and gastritis?

*Yang D, He L, Tong WH, Jia ZF, Su TR, Wang Q*

### Randomized Clinical Trial

- 6357 Drainage fluid and serum amylase levels accurately predict development of postoperative pancreatic fistula

*Jin S, Shi XJ, Wang SY, Zhang P, Lv GY, Du XH, Wang GY*

### CASE REPORT

- 6365 Interventional endoscopic ultrasound for a symptomatic pseudocyst secondary to gastric heterotopic pancreas

*Jin HB, Lu L, Yang JF, Lou QF, Yang J, Shen HZ, Tang XW, Zhang XF*

## ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Gabriele Grassi, MD, PhD, Associate Professor, Department of Life Sciences, University Hospital of Cattinara, 34149 Trieste, Italy

## AIMS AND SCOPE

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

## INDEXING/ABSTRACTING

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

## FLYLEAF

### I-IX Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Fen-Fen Zhang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ke Chen*  
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

### EDITORS-IN-CHIEF

**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

### EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Yuan Qi, Vice Director  
Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

### PUBLISHER

Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE  
September 14, 2017

### COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

### SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

### INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/getinfo/204>

ONLINE SUBMISSION  
<http://www.f6publishing.com>



## Retrospective Study

# Body mass index does not affect the survival of pancreatic cancer patients

Qing-Long Jiang, Cheng-Feng Wang, Yan-Tao Tian, Huang Huang, Shui-Sheng Zhang, Dong-Bing Zhao, Jie Ma, Wei Yuan, Yue-Min Sun, Xu Che, Jian-Wei Zhang, Yun-Mian Chu, Ya-Wei Zhang, Ying-Tai Chen

Qing-Long Jiang, Cheng-Feng Wang, Yan-Tao Tian, Shui-Sheng Zhang, Dong-Bing Zhao, Jie Ma, Wei Yuan, Yue-Min Sun, Xu Che, Jian-Wei Zhang, Yun-Mian Chu, Ying-Tai Chen, Department of Pancreatic and Gastric Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Huang Huang, Ya-Wei Zhang, Department of Surgery, Yale School of Medicine, Yale Cancer Center, New Haven, CT 06511, United States

**Author contributions:** Jiang QL, Wang CF, Chen YT and Zhang YW designed the research; Tian YT, Huang H, Zhang SS, Zhao DB and Ma J collected the data; Yuan W, Sun YM, Che X and Zhang JW analyzed the data; Jiang QL and Chen YT wrote the paper; all authors contributed to this manuscript.

**Supported by** National Natural Science Foundation of China, No. 81401947; Beijing Nova Program, No. xxjh2015A090; Cancer Hospital of the Chinese Academy of Medical Sciences, No. LC2015L11.

**Institutional review board statement:** The study was reviewed and approved by the Cancer Hospital of the Chinese Academy of Medical Sciences.

**Informed consent statement:** All study participants provided informed written consent prior to study enrolment.

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest related to this study.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

[licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Ying-Tai Chen, MD, PhD, Department of Pancreatic and Gastric Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [yingtai.chen@yale.edu](mailto:yingtai.chen@yale.edu)  
Telephone: +86-10-87787120  
Fax: +86-10-87787123

**Received:** February 22, 2017

**Peer-review started:** February 24, 2017

**First decision:** April 7, 2017

**Revised:** May 5, 2017

**Accepted:** July 12, 2017

**Article in press:** July 12, 2017

**Published online:** September 14, 2017

## Abstract

### AIM

To evaluate the association of body mass index (BMI) with the overall survival of pancreatic ductal adenocarcinoma (PDAC) patients.

### METHODS

A retrospective analysis of PDAC patients diagnosed in the National Cancer Center of China between January 1999 and December 2014 was performed. These patients were categorized into four BMI groups ( $< 18.5$ ,  $18.5-22.9$ ,  $23-27.4$  and  $\geq 27.5$  kg/m<sup>2</sup>).  $\chi^2$  tests for comparison of the proportions of categorical variables, and Student's *t*-test or Mann-Whitney test for continuous variables were employed. Survival analysis was performed with the Kaplan-Meier method. Their HRs of mortality and 95% CIs were estimated using the Cox proportional hazards model.

## RESULTS

With a median age of 59.6 years (range: 22.5-84.6 years), in total 1783 PDAC patients were enrolled in this study. Their mean usual BMI was  $24.19 \pm 3.53$  for the whole cohort. More than half of the patients (59.3%) experienced weight loss during the disease onset and progression. Compared with healthy-weight individuals, newly diagnosed patients who were overweight or obese had more severe weight loss during their disease onset and progression ( $P < 0.001$ ). Individuals who were overweight or obese were associated with positive smoking history ( $P < 0.001$ ). A significant difference in comorbidity of diabetes ( $P = 0.044$ ) and coronary artery disease ( $P < 0.001$ ) was identified between high BMI and normal-weight patients. After a median follow-up of 8 mo, the survival analysis showed no association between BMI and the overall survival ( $P = 0.90$ ,  $n = 1783$ ). When we stratified the whole cohort by pancreatic cancer stage, no statistically significant association between BMI and overall survival was found for resectable ( $P = 0.99$ ,  $n = 217$ ), unresectable locally advanced ( $P = 0.90$ ,  $n = 316$ ) and metastatic patients ( $P = 0.88$ ,  $n = 1250$ ), respectively. The results did not change when we used the BMI at diagnosis.

## CONCLUSION

Our results showed no significance of BMI for the overall survival of PDAC patients.

**Key words:** Body mass index; Pancreatic cancer; Overweight; Smoking history; Survival analysis

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** It remains controversial whether body mass index (BMI) influences the prognosis of pancreatic cancer. The strengths of this study included a large quantity of patients and the accurate BMI categorization according the Asian criterion. To the best of our knowledge, it is the largest study in Asia to evaluate the prognostic role of BMI on the overall survival of pancreatic cancer patients. Our results showed no significant influence of BMI on the overall survival of pancreatic ductal adenocarcinoma patients and are consistent with those of many other studies.

Jiang QL, Wang CF, Tian YT, Huang H, Zhang SS, Zhao DB, Ma J, Yuan W, Sun YM, Che X, Zhang JW, Chu YM, Zhang YW, Chen YT. Body mass index does not affect the survival of pancreatic cancer patients. *World J Gastroenterol* 2017; 23(34): 6287-6293 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i34/6287.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i34.6287>

## INTRODUCTION

Pancreatic cancer is a devastating malignant cancer, with a 5-year survival rate of  $< 6\%$ <sup>[1]</sup>. The survival

length of patients is greatly influenced by disease stage at diagnosis, but few other survival markers have been well characterized<sup>[2-4]</sup>.

Excessive adipose can impair both humoral and cellular immunity, which may be important in the development of pancreatic cancer. Although many studies have demonstrated that a high body mass index (BMI), an indirect measure of adiposity, is associated with increased risk of developing pancreatic cancer, it remains controversial whether BMI influences the prognosis of pancreatic cancer. Several studies have reported that a higher BMI is associated with decreased survival of pancreatic cancer patients<sup>[5-10]</sup>, whereas other results informed that BMI was not a statistically significant prognostic factor<sup>[11-15]</sup>. Tsai *et al*<sup>[16]</sup> even expressed improved long-term survival of pancreatic cancer patients with higher BMIs. As such, we conducted a single-center, large-scale retrospective study to determine the associations between BMI and overall survival of Chinese pancreatic ductal adenocarcinoma (PDAC) patients.

## MATERIALS AND METHODS

### Patients

The medical records of all patients diagnosed with PDAC from January 1999 to December 2014 in the Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College were studied by retrospective chart review. All patients had histological diagnosis of PDAC confirmed by pathology. Clinical information was systematically abstracted from these patients' medical records using an established abstraction form by trained individuals with a medical background. For the whole cohort, the extracted information included age, sex, weight, height, smoking history, alcohol use history, previous history of cancer, and previous abdominal surgery. The patients' height and weight of 1 year prior to diagnosis and at diagnosis were all recorded. Comorbidities were also recorded, such as diabetes, coronary artery disease and hypertension. Clinical disease stage was defined on the basis of the patients' initial computed tomographic images and endoscopic ultrasound reports, as stated in the American Joint Committee on Cancer Staging Manual using the TNM staging system. Follow-up information was obtained through telephone-based interviews, as well as from the records of outpatient follow-up, if any. The primary outcome variable was overall survival, defined for patients as the period from date of diagnosis to date of death. Informed consent was obtained from all individual participants included in the study.

### Statistical analysis

BMI was calculated as weight (kg) divided by the square of height ( $m^2$ ), using self-reported usual adult height and weight. According to the Asian criterion, BMI was classified as underweight ( $< 18.5 \text{ kg}/m^2$ ),

**Table 1** Demographics, comorbidity and stage of patients grouped according to body mass index

Characteristic	All patients	BMI category, kg/m <sup>2</sup>				P value
		< 18.5	18.5-22.9	23-27.4	≥ 27.5	
Patients	1783	98 (5.5)	588 (33.0)	791 (44.4)	306 (17.2)	
Sex						0.97
Male	1009 (56.6)	54 (3.0)	334 (18.7)	445 (25.0)	176 (9.9)	
Female	774 (43.4)	44 (2.5)	254 (14.2)	346 (19.4)	130 (7.3)	
Male/female ratio	1.30	1.23	1.31	1.29	1.35	
BMI as kg/m <sup>2</sup> , mean ± SD	24.19 ± 3.53	17.60 ± 0.84	21.16 ± 1.23	25.07 ± 1.29	29.68 ± 2.11	
Age at diagnosis in yr						
Median	59.6	62.3	59.0	59.6	59.7	
Range	22.5-84.6	28.7-81.7	22.5-80.2	30.7-84.6	26.0-84.6	
Weight loss as % of usual adult weight						
None	725 (40.7)	61 (3.4)	333 (18.7)	299 (16.8)	32 (1.8)	
> 0, ≤ 10%	652 (36.6)	23 (1.3)	190 (10.7)	321 (18.0)	118 (6.6)	
> 10%	406 (22.8)	14 (0.79)	65 (3.6)	171 (9.6)	156 (8.7)	< 0.0001
Any weight loss	1058 (59.3)	37 (2.1)	255 (14.3)	492 (27.6)	274 (15.4)	< 0.0001
Smoking						0.0003
Never	1243 (69.7)	72 (4.1)	408 (22.9)	568 (31.9)	195 (10.9)	
Ever	527 (29.6)	22 (1.2)	176 (9.9)	220 (12.3)	109 (6.1)	
Alcohol						0.42
Never	1377 (77.2)	76 (4.3)	465 (26.1)	614 (34.4)	222 (12.5)	
Ever	398 (22.3)	21 (1.2)	121 (6.8)	174 (9.8)	82 (4.6)	
Comorbidity						
Diabetes	398 (22.3)	13 (0.7)	125 (7.0)	196 (11.0)	64 (3.6)	0.044
Coronary artery disease	247 (13.9)	8 (0.4)	46 (2.6)	166 (9.3)	27 (1.5)	< 0.0001
Hypertension	267 (15.0)	9 (0.5)	88 (4.9)	111 (6.2)	59 (3.3)	0.055
Previous history of cancer	14 (0.8)	1 (0.06)	6 (0.34)	6 (0.34)	1 (0.06)	0.72
Previous abdominal surgery	87 (4.9)	7 (0.39)	34 (1.9)	34 (1.9)	12 (0.67)	0.35
Stage group						0.89
Resectable	217 (12.2)	15 (0.84)	73 (4.1)	93 (5.2)	36 (2.0)	
Unresectable locally advanced	316 (17.7)	17 (0.95)	108 (6.1)	143 (8.0)	48 (2.7)	
Metastatic	1250 (70.1)	66 (3.7)	407 (22.8)	555 (31.1)	222 (12.5)	

Data are *n* (%), unless otherwise indicated. BMI: Body mass index.

healthy weight (18.5-22.9 kg/m<sup>2</sup>), overweight (23.0-27.4 kg/m<sup>2</sup>), and obese (≥ 27.5 kg/m<sup>2</sup>).  $\chi^2$  tests for comparison of the proportions of categorical variables, and Student's *t*-test or Mann-Whitney test for continuous variables were employed. The unconditional logistic regression model was used to estimate the ORs and 95% CIs for the associations among BMI, clinical characteristics and overall survival of PDAC patients, and for the PDAC subtypes in different clinical stages. Survival analysis was performed by the Kaplan-Meier method. The group with BMI 18.5-22.9 kg/m<sup>2</sup> was the reference group. All *P*-values presented were two-sided, and all analyses were carried out using SAS Software Version 9.2 (SAS Institute, Cary, NC, United States). Statistical significance was defined as a *P* value of < 0.05.

## RESULTS

### Clinical characteristics

Data were extracted from a total of 1783 subjects with PDAC who had complete medical history. Histological or cytological diagnosis was obtained from the primary pancreatic lesion or metastases in all cases. The pathology was confirmed by two pathologists. Baseline characteristics of 1783 patients with pancreatic cancer are listed in Table 1. Of those subjects, 1009 (56.6%)

were male, with a median age of 59.6 years. Among the total, 29.6% patients had a positive smoking history, 22.3% had a drinking history, and 22.3%, 13.9% and 15.0% patients had diabetes, coronary artery disease and hypertension at diagnosis of pancreatic cancer as concomitant comorbidities, respectively.

Among those with known disease stage, 217 had potentially resectable tumors at the time of diagnosis, 316 had locally advanced disease, and 1250 had distant metastasis. Their mean baseline BMI was 24.19 kg/m<sup>2</sup>, and 44.4% of the patients were classified as overweight and 17.2% as obese. More than half of the patients (59.3%) experienced weight loss during their disease onset progression. Compared with healthy-weight individuals, the newly diagnosed patients who were overweight or obese had more severe weight loss during the disease onset progression (*P* < 0.001). Individuals who were overweight or obese are associated with a positive smoking history (*P* = 0.0003). A significant difference in comorbidity of diabetes (*P* = 0.044) and coronary artery disease (*P* < 0.001) was identified between high BMI values and normal-weight patients.


### Survival analysis

The median follow-up duration was 8 mo for all cases. Median overall survival for each BMI category (kg/m<sup>2</sup>)

**Table 2** Pancreatic cancer survival by usual adult body mass index category

Stage group	BMI category	<i>n</i>	Median overall survival, mo (95%CI)	HR	95%CI	<i>P</i> value	<i>P</i> <sub>trend</sub> value
Overall	< 18.5	98	8.0 (5.8-11.3)	1.12	0.83-1.52	0.45	0.90
	18.5-22.9	588	9.7 (8.7-11.1)	1.00	Ref.	Ref.	
	23-27.4	791	9.5 (8.6-10.5)	0.99	0.87-1.14	0.92	
	≥ 27.5	306	9.8 (7.6-11.2)	1.05	0.88-1.25	0.61	
Resectable	< 18.5	15	11.1 (3.3-19.3)	1.92	0.74-5.01	0.18	0.99
	18.5-22.9	73	15.6 (10.1-21.3)	1.00	Ref.	Ref.	
	23-27.4	93	16.7 (11.9-27.4)	0.92	0.59-1.44	0.71	
	≥ 27.5	36	16.2 (4.5-23.7)	1.13	0.61-2.08	0.70	
Unresectable locally advanced	< 18.5	17	7.0 (3.4-26.1)	0.83	0.38-1.84	0.65	0.90
	18.5-22.9	108	8.7 (7.3-11.7)	1.00	Ref.	Ref.	
	23-27.4	143	8.6 (6.8-11.5)	1.03	0.73-1.45	0.86	
	≥ 27.5	48	8.6 (4.9-15.6)	0.95	0.59-1.54	0.84	
Metastatic	< 18.5	66	4.9 (2.8-8.0)	1.07	0.76-1.51	0.70	0.88
	18.5-22.9	407	5.5 (4.0-6.4)	1.00	Ref.	Ref.	
	23-27.4	555	5.7 (3.7-6.8)	0.99	0.84-1.16	0.89	
	≥ 27.5	222	5.6 (3.3-7.7)	1.02	0.84-1.27	0.76	

BMI: Body mass index.

**Figure 1** Unadjusted Kaplan-Meier analysis of overall survival among 1783 pancreatic cancer patients according to usual adult body mass index category. BMI: Body mass index.

was as follows: < 18.5: 8 mo; 18.5-22.9: 9.7 mo; 23.0-27.4: 9.5 mo; and ≥ 27.5: 9.8 mo (Table 2). Kaplan-Meier survival comparisons (Figure 1) showed no association between BMI and the overall survival of pancreatic cancer patients ( $P > 0.05$ ). When we stratified the whole cohort by pancreatic cancer stage, no statistically significant association between BMI and overall survival was found for resectable ( $P = 0.99$ ,  $n = 217$ ), unresectable locally advanced ( $P = 0.90$ ,  $n = 316$ ) and metastatic ( $P = 0.88$ ,  $n = 1250$ ) patients. The multivariate Cox regression survival analysis showed the same results (Figures 2 and 3). Considering the effect of cancer-related weight loss among patients, the results did not change when we used the BMI at diagnosis.


## DISCUSSION

Overweight/obesity and its related morbidities represent a growing health problem, claiming 2.8 million lives annually according to the WHO 2010 Global Report<sup>[17]</sup>.

Obesity has been found to be associated with a wide array of morbidities, including cardiovascular disease, chronic kidney disease, sleeping disorder, type 2 diabetes, and several forms of cancer. Obesity is considered to be an adverse prognostic factor in malignancies, such as breast and colon cancers<sup>[18,19]</sup>. In our study, a significant difference in comorbidity of diabetes and coronary artery disease was identified between high BMI values and normal-weight patients. But survival analysis showed that BMI did not affect the survival of pancreatic cancer patients.

Previous studies conferring the role of BMI were mainly carried out in cohorts of United States adults, which presented a higher percentage of obese (BMI ≥ 30) and very obese (BMI ≥ 35) patients and the BMI categorization as opposed to our Asian criterion. For a Mayo Clinic cohort of patients covering all stages of pancreatic cancer respectively, including early-stage patients who underwent surgery, McWilliams *et al*<sup>[6]</sup> reported that the BMI at diagnosis had a negative impact on survival. This was particularly pronounced in the very obese patients with a BMI of 35 to 39.99 kg/m<sup>2</sup> (HR = 1.32, 95%CI: 1.08-1.62) and > 40 kg/m<sup>2</sup> (HR = 1.60, 95%CI: 1.26-2.04), respectively. In a case control study designed to assess the risk of developing pancreatic cancer in overweight persons, Li *et al*<sup>[5]</sup> described a shorter survival period for patients who were overweight or obese during the year prior to diagnosis. Another study from Olson *et al*<sup>[11]</sup> demonstrated that obesity was non-significantly associated with poorer survival of PDAC patients, particularly in the resected group (HR = 1.62, 95%CI: 0.76-3.44). The experience from Chen *et al*<sup>[20]</sup> showed that a higher BMI increases the risk for postoperative complications after pancreatotomy in the Chinese population. However, Tsai *et al*<sup>[16]</sup> reported that obese patients undergoing pancreaticoduodenectomy for pancreatic cancer had improved long-term survival, independent of known






**Figure 2** Body mass index and survival of pancreatic cancer patients by stage. Forest plots within stage groupings for resectable, locally advanced and metastatic patients at initial diagnosis of pancreatic cancer are shown.

clinicopathologic factors. Big controversy has lasted about the real role of BMI on pancreatic cancer for years. The results in this study need to be replicated in more studies with larger sample sizes with a greater power.

Limited information was available on the possible effect of weight loss on the survival of PDAC patients. As we know, loss of weight is usual for pancreatic cancer patients either before or after diagnosis. In our study, more than half of the patients experienced weight loss during their disease progression, especially in the obese group, which might explain why the obesity-specific co-morbidities such as diabetes were not more prevalent in the obese group compared with the normal populations. Dalal *et al*<sup>[21]</sup> believed



**Figure 3** Kaplan-Meier analysis. A: Unadjusted Kaplan-Meier analysis among 217 pancreatic cancer patients undergoing radical resection according to BMI category; B: Unadjusted Kaplan-Meier analysis among 316 unresectable locally advanced pancreatic cancer patients according to BMI category; C: Unadjusted Kaplan-Meier analysis among 1250 pancreatic cancer patients with distant metastasis according to BMI category. BMI: Body mass index.

that obese patients experienced higher loss in weight, skeletal muscle and visceral adipose tissue, which may contribute to poorer survival of pancreatic cancer patients. So, we carried out the survival analysis using patients' BMIs at usual time as well as at diagnosis, but the results did not change.

The strengths of this study included a large quantity of patients and the accurate BMI categorization according to the Asian criterion. To the best of our knowledge, it is the largest study in Asia to evaluate the prognostic role of BMI on the overall survival of pancreatic cancer patients. Our results showed no significant influence of BMI on the overall survival of PDAC patients and are consistent with those of many other studies<sup>[11-15]</sup>. We, however, must admit that

there are several limitations for the current study. The retrospective nature of this study can be associated with selection bias as well as increased risk of differential misclassification bias. Another shortcoming was the limited generalizability because the entire study population came from a single hospital.

In conclusion, BMI has not shown any clear relationship with the survival outcome of pancreatic cancer. More studies are needed to validate this finding and evaluate the mechanism behind the observation.

## COMMENTS

### Background

Excessive adipose can impair both humoral and cellular immunity, which may be important in the development of pancreatic cancer. Although many studies have demonstrated that a high body mass index (BMI), an indirect measure of adiposity, is associated with increased risk of developing pancreatic cancer, it remains controversial whether BMI influences the prognosis of pancreatic cancer. Several studies have reported that a higher BMI is associated with decreased survival of pancreatic cancer patients, whereas other results informed that BMI was not a statistically significant prognostic factor.

### Research frontiers

The authors conducted a single-center, large-scale retrospective study to determine the associations between BMI and overall survival of Chinese pancreatic ductal adenocarcinoma (PDAC) patients.

### Innovations and breakthroughs

To the best of our knowledge, this is the largest study in Asia to evaluate the prognostic role of BMI on the overall survival of pancreatic cancer patients.

### Applications

In this study, BMI did not affect the survival of pancreatic cancer patients. The results provide more insight into the role of BMI on pancreatic cancer.

### Peer-review

The present retrospective study demonstrated that BMI has no relationship with survival of PDAC in a large single center. The paper has high value for inclusion in the current literature on the topic.

## REFERENCES

- 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
- 2 Zou L, Zhong R, Shen N, Chen W, Zhu B, Ke J, Lu X, Zhang T, Lou J, Wang Z, Liu L, Qi L, Miao X. Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. *Eur J Cancer* 2014; **50**: 193-203 [PMID: 24054979 DOI: 10.1016/j.ejca.2013.08.014]
- 3 Elena JW, Steplowski E, Yu K, Hartge P, Tobias GS, Brotzman MJ, Chanock SJ, Stolzenberg-Solomon RZ, Arslan AA, Bueno-de-Mesquita HB, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Allen NE, Amundadottir L, Bao Y, Boeing H, Boutron-Ruault MC, Buring JE, Gaziano JM, Giovannucci EL, Duell EJ, Hallmans G, Howard BV, Hunter DJ, Hutchinson A, Jacobs KB, Kooperberg C, Kraft P, Mendelsohn JB, Michaud DS, Palli D, Phillips LS, Overvad K, Patel AV, Sansbury L, Shu XO, Simon MS, Slimani N, Trichopoulos D, Visvanathan K, Virtamo J, Wolpin BM, Zeleniuch-Jacquotte A, Fuchs CS, Hoover RN, Gross M. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. *Cancer Causes Control* 2013; **24**: 13-25 [PMID: 23112111 DOI: 10.1007/s10552-012-0078-8]
- 4 Jaacks LM, Gordon-Larsen P, Mayer-Davis EJ, Adair LS, Popkin B. Age, period and cohort effects on adult body mass index and overweight from 1991 to 2009 in China: the China Health and Nutrition Survey. *Int J Epidemiol* 2013; **42**: 828-837 [PMID: 23771721 DOI: 10.1093/ije/dyt052]
- 5 Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. *JAMA* 2009; **301**: 2553-2562 [PMID: 19549972 DOI: 10.1001/jama.2009.886]
- 6 McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, de Andrade M, Reid-Lombardo K, Bamlet WR. Obesity adversely affects survival in pancreatic cancer patients. *Cancer* 2010; **116**: 5054-5062 [PMID: 20665496 DOI: 10.1002/cncr.25465]
- 7 Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Robinson DA, Stampfer MJ, Giovannucci EL, Wolpin BM. Prediagnostic body mass index and pancreatic cancer survival. *J Clin Oncol* 2013; **31**: 4229-4234 [PMID: 24145341 DOI: 10.1200/JCO.2013.51.7532]
- 8 Kasenda B, Bass A, Koeberle D, Pestalozzi B, Borner M, Herrmann R, Jost L, Lohri A, Hess V. Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. *BMC Cancer* 2014; **14**: 728 [PMID: 25266049 DOI: 10.1186/1471-2407-14-728]
- 9 Shi YQ, Yang J, Du P, Xu T, Zhuang XH, Shen JQ, Xu CF. Effect of Body Mass Index on Overall Survival of Pancreatic Cancer: A Meta-Analysis. *Medicine* (Baltimore) 2016; **95**: e3305 [PMID: 27057903 DOI: 10.1097/MD.0000000000003305]
- 10 Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, Evans DB. Influence of obesity on cancer-related outcomes after pancreatotomy to treat pancreatic adenocarcinoma. *Arch Surg* 2009; **144**: 216-221 [PMID: 19289659 DOI: 10.1001/archsurg.2008.580]
- 11 Olson SH, Chou JF, Ludwig E, O'Reilly E, Allen PJ, Jarnagin WR, Bayuga S, Simon J, Gonen M, Reisacher WR, Kurtz RC. Allergies, obesity, other risk factors and survival from pancreatic cancer. *Int J Cancer* 2010; **127**: 2412-2419 [PMID: 20143395 DOI: 10.1002/ijc.25240]
- 12 Gong Z, Holly EA, Bracci PM. Obesity and survival in population-based patients with pancreatic cancer in the San Francisco Bay Area. *Cancer Causes Control* 2012; **23**: 1929-1937 [PMID: 23015286 DOI: 10.1007/s10552-012-0070-3]
- 13 Pelucchi C, Galeone C, Polesel J, Manzari M, Zucchetto A, Talamini R, Franceschi S, Negri E, La Vecchia C. Smoking and body mass index and survival in pancreatic cancer patients. *Pancreas* 2014; **43**: 47-52 [PMID: 24177141 DOI: 10.1097/MPA.0b013e3182a7c74b]
- 14 Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. *Pancreas* 2011; **40**: 931-937 [PMID: 21747317 DOI: 10.1097/MPA.0b013e318215a9b1]
- 15 Gaujoux S, Torres J, Olson S, Winston C, Gonen M, Brennan MF, Klimstra DS, D'Angelica M, DeMatteo R, Fong Y, House M, Jarnagin W, Kurtz RC, Allen PJ. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. *Ann Surg Oncol* 2012; **19**: 2908-2916 [PMID: 22411205 DOI: 10.1245/s10434-012-2301-y]
- 16 Tsai S, Choti MA, Assumpcao L, Cameron JL, Gleisner AL, Herman JM, Eckhauser F, Edil BH, Schulick RD, Wolfgang CL, Pawlik TM. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study. *J Gastrointest Surg* 2010; **14**: 1143-1150 [PMID: 20431978 DOI: 10.1007/s11605-010-1201-3]
- 17 Esteghamati A, Mazaheri T, Vahidi Rad M, Noshad S. Complementary and alternative medicine for the treatment of obesity: a critical review. *Int J Endocrinol Metab* 2015; **13**: e19678 [PMID: 25892995 DOI: 10.5812/ijem.19678]
- 18 Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R,

- Hortobagyi GN, Cristofanilli M. Prognostic value of body mass index in locally advanced breast cancer. *Clin Cancer Res* 2008; **14**: 1718-1725 [PMID: 18347172 DOI: 10.1158/1078-0432.CCR-07-1479]
- 19 **Siegel EM**, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D. The effects of obesity and obesity-related conditions on colorectal cancer prognosis. *Cancer Control* 2010; **17**: 52-57 [PMID: 20010519]
  - 20 **Chen YT**, Deng Q, Che X, Zhang JW, Chen YH, Zhao DB, Tian YT, Zhang YW, Wang CF. Impact of body mass index on complications following pancreatectomy: Ten-year experience at National Cancer Center in China. *World J Gastroenterol* 2015; **21**: 7218-7224 [PMID: 26109808 DOI: 10.3748/wjg.v21.i23.7218]
  - 21 **Dalal S**, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, Reyes-Gibby CC, Bedi D, Bruera E. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. *J Pain Symptom Manage* 2012; **44**: 181-191 [PMID: 22695045 DOI: 10.1016/j.jpainsymman.2011.09.010]

**P- Reviewer:** Cesaretti M, Luyer M    **S- Editor:** Gong ZM  
**L- Editor:** Filipodia    **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

